Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2

i i i i i T. Safra,' F. Muggia/ S. Jeffers, D. D. Tsao-Wei, S. Groshen, O. Lyass, R. Henderson, G. Berry & A. Gabizon ^USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, Stanford Pathology Consultants, Stanford University Medical Center, Stanford, California, USA; Sharet Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

[1]  A. Gabizon,et al.  Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors , 1998 .

[2]  Z. Pavelic,et al.  Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. , 1993, In vivo.

[3]  J. Mason,et al.  Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation , 1977, The American journal of surgical pathology.

[4]  F. Torti,et al.  The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Newman,et al.  Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  G. Hortobagyi,et al.  Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[10]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[11]  A. A. Gabizon.  Liposomal anthracyclines. , 1994, Hematology/oncology clinics of North America.

[12]  D. Northfelt,et al.  Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma , 1997, Clinical pharmacology and therapeutics.

[13]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Torti,et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. , 1983, Annals of internal medicine.

[15]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[17]  F. Muggia.  Doxil in breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Speyer,et al.  Strategies for reduction of anthracycline cardiac toxicity. , 1998, Seminars in oncology.

[19]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[20]  Y. Barenholz,et al.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. , 1982, Cancer research.

[21]  C. Orlandini,et al.  Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.